Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation, alleging that the company made misleading statements regarding its financial health and the impact of customer spending on its business [3][4]. Financial Performance - 3D Systems reported a Q4 non-GAAP loss of $0.19 per share, missing consensus estimates by $0.08 [6] - Q4 revenue was $111 million, representing a 3.4% year-over-year decline and falling short of expectations by $4.17 million [6] - Full-year revenue for 2024 was $440.1 million, a 10% decline year-over-year attributed to lower hardware sales and macroeconomic challenges [6] - The company experienced a $9 million revenue reduction in Q4 due to revised accounting estimates for its Regenerative Medicine Program [6] - In Q1 2025, revenue was $94.5 million, an 8% year-over-year decline, and below the consensus estimate of $99.5 million [6] - The net loss for Q1 2025 was $37 million (or $0.28 per share), more than double the $16 million loss in Q1 2024 [6] - An adjusted loss of $0.21 per share was reported, worse than the expected $0.14 loss [6] - The adjusted EBITDA was negative at $23.9 million, compared to a $20.1 million loss in Q1 2024 [6] Class Action Details - The class action lawsuit covers investors who purchased securities between August 13, 2024, and May 12, 2025 [1] - Investors have until August 12, 2025, to file a lead plaintiff motion [1] - The lawsuit claims that 3D Systems failed to disclose the negative impact of weakened customer spending and changes in its partnership with United Therapeutics Corporation [3]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sc ...

SAN JOSE, Calif., July 21, 2025 /PRNewswire/ -- Sanmina Corporation (NASDAQ: SANM) announced today that it will host its third quarter fiscal 2025 earnings conference call on Monday, July 28, 2025 at 5:00 PM ET. The live webcast presentation and supporting materials will be available on the Sanmina website at www.sanmina.com in the Investor Relations section. A webcast replay will be available at the same location upon the conclusion of the event.About SanminaSanmina Corporation, a Fortune 500 company, is a ...

Core Insights - Wuxi Lead Intelligent Equipment Co., Ltd. (LEAD) Chairman Mr. Yanqing Wang received the Best International Interview award from Battery-News for his insights on battery manufacturing and electrification trends [1][3][5] Group 1: Recognition and Awards - The award was based on an interview conducted in March 2024, which was praised for its clarity and strategic foresight [3][5] - The recognition highlights LEAD's reputation as a pioneer in advanced battery production solutions, particularly in all-solid-state battery manufacturing [4] Group 2: Industry Insights - Mr. Wang's interview discussed the transformation in battery manufacturing and the rise of intelligent automotive technologies [3][4] - The perspectives shared reflect LEAD's commitment to innovation, sustainability, and cross-border collaboration in the energy sector [4]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][6][7]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [3]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on additive manufacturing for human organ transplantation [4]. Financial Performance - In Q4 2024, 3D Systems reported non-GAAP earnings-per-share of -$0.19, missing estimates by $0.08, with sales revenue of $111 million, a 3.4% year-over-year decline [8]. - For the full year 2024, sales were $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [8]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [9]. Market Response - Following the Q4 2024 results, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [8]. - After the Q1 2025 results, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [10]. Legal Allegations - The lawsuit alleges that during the Class Period, the company and its officers made materially false and misleading statements, including underestimating the impact of weakened customer spending and overstating the resilience of the business [6][7]. - The updated milestone criteria in the United Partnership were claimed to negatively impact the company's Regenerative Medicine Program revenue [7].

First Transformative Achievement Under Our Mergers & Acquisitions Program Roseville, Minnesota, June 24, 2025 (GLOBE NEWSWIRE) -- SecureTech Innovations, Inc. (OTC: SCTH), a pioneering technology company advancing artificial intelligence, industrial 3D printing and manufacturing technologies, cybersecurity, and digital infrastructure solutions, is excited to announce its landmark acquisition of AI UltraProd Group (“AI UltraProd”). This strategic expansion strengthens SecureTech’s ability to drive innovation ...

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on 3D printing organs for transplantation [4][5]. Financial Performance - In March 2025, 3D Systems projected revenue for 2025 to be between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP Gross Profit Margin of 37% to 39% and non-GAAP Operating Expense of $200 million to $220 million [7]. - The company reported a Q4 2024 non-GAAP earnings-per-share of -$0.19, missing estimates, and a sales revenue of $111 million, down 3.4% year-over-year [9]. - For full-year 2024, sales were reported at $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, dropping 20.96% to $2.15 per share on March 27, 2025, and further declining 26.6% to $1.87 per share on May 13, 2025 [9][11]. Allegations in Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements about the company's business resilience and the impact of weakened customer spending, as well as failing to disclose the negative effects of updated milestone criteria on the Regenerative Medicine Program revenue [8].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors regarding its business prospects and financial performance [1][2]. Group 1: Allegations and Financial Performance - The complaint alleges that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [2]. - The updated milestone criteria in the United Partnership are claimed to negatively impact the revenue of the Company's Regenerative Medicine Program [2]. - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million, and a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, deeper than the consensus estimate of a loss of $0.14, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The Company attributed its disappointing results to a decline in material sales, particularly due to inventory management issues in the dental segment of its Healthcare Solutions [4]. - 3D Systems withdrew its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty [4]. - Following the Q1 results announcement, the stock price fell $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors about its business prospects, particularly regarding customer spending and revenue impacts from updated milestone criteria in its Regenerative Medicine Program [1][2]. Financial Performance - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million. The company also reported a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, worse than the consensus estimate of a loss of $0.14 per share, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The company withdrew its full-year 2025 outlook due to prolonged softness in customer capital spending and macroeconomic uncertainty, resulting in a further stock price decline of $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Insights - The article discusses the importance of a hybrid investing strategy, particularly the GARP (Growth at a Reasonable Price) approach, in navigating market uncertainties and achieving better investment outcomes [1][2]. GARP Strategy - GARP combines principles of both growth and value investing, focusing on stocks that are undervalued yet have sustainable growth potential [4]. - The PEG (Price/Earnings Growth) ratio is a key metric in GARP investing, helping to identify stocks with solid future potential by relating P/E ratios to future earnings growth rates [5][6]. Stock Analysis - Four stocks are highlighted as successful examples of the GARP strategy: Flex Ltd. (FLEX), CVS Health (CVS), Urban Outfitters (URBN), and Exelixis (EXEL) [3][11]. - FLEX has a historical growth rate of 35.1% and a Zacks Rank of 2, indicating strong potential [12]. - CVS Health has a long-term expected growth rate of 11.4% and also holds a Zacks Rank of 2 [14]. - Urban Outfitters has a 20% earnings growth rate over the last five years and a Zacks Rank of 1, making it a strong GARP candidate [15]. - Exelixis boasts a long-term expected earnings growth rate of 21.2% and a Zacks Rank of 2 [17]. Screening Criteria - The stocks selected for GARP investment must have a PEG ratio below the industry median, a solid earnings outlook, and a Zacks Rank of 1 or 2 [8][9]. - Additional criteria include a market capitalization greater than $1 billion and an average 20-day trading volume exceeding 50,000 [9][10].